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ABSTRACT:
Liver targeting drug delivery systems can improve the 
delivery of several drugs useful in the treatment of liver 
disorders such as cirrhosis and liver cancer. The 
objective of this study was to prepare the biodegradable 
nanoparticles containing curcumin, a well-known 
hepatoprotective agent and further to evaluate the liver 
targetability and sustained release of curcumin with the 
developed nanoformulation. Curcumin nanoparticles 
were prepared by double emulsion (w/o/w) solvent 
evaporation method using different drug polymer ratios. 
Poly-ε-caprolactone was used in the preparation. The 
prepared formulations were evaluated for particles size, 
surface potential, entrapment efficiency, in vitro release, 
drug polymer interaction. Four different formulations 
CNP1, CNP2, CNP3 and CNP4 were prepared. 
Optimized formulation (CNP3) was evaluated for 
pharmacokinetics and hepatoprotective activity in CCl4
induced liver toxicity model after i.v. administration. 
Optimized formulation was selected based on the size, 
entrapment efficiency and release characteristics. 
Curcumin i.v. solution and oral suspension form were 
used as the reference. Particle size of all formulations 
was in the range of 300-470 nm and the entrapment 
efficiencies were in the range of 75-85 %.  Drug release 
from the nanoparticles was sustained both in vitro and in 
vivo. Nanoparticle formulation tested in vivo
demonstrated better pharmacokinetics and 
pharmacodynamics compared to the reference. Drug 
levels in the liver were significantly higher with 
nanoparticular formulation. Thus, this study 
successfully prepared a nanoparticular formulation 
containing curcumin with polycaprolactone as the 
polymer. With the developed formulation better liver 
targetability was achieved. 
Key words: cirrhosis, liver targeting, nanoparticles, 
curcumin, pharmacokinetics, sustained drug release, 
hepatoprotective activity.
INTRODUCTION
       Curcumin (diferuloyl methane; 1, 7-Bis-(4-hydroxy-
3-methoxyphenyl)-hepta-1, 6-diene-3, 5-dione) is a 
major constituent found in the spice turmeric, which is 
derived from the rhizomes of Curcuma longa L. It is 
commonly used as a dietary spice and colouring agent in
cooking and is used as an herb in traditional Indian and 
Chinese medicine. Curcumin possesses diverse 
pharmacological effects including anti-inflammatory, 
antioxidant, anticancer, antidiabetic, antirheumatic, 
angiogenic, antifertility, antiviral and anti-infectious 
activities and wound healing properties.1 Despite 
curcumin’s multiple medicinal benefits, low oral 
bioavailability of curcumin continues to be highlighted 
as a major challenge in developing formulations for 
clinical efficacy. Lower serum and tissue levels of 
curcumin are observed irrespective of the route of 
administration due to extensive intestinal and hepatic 
metabolism and rapid elimination thus restraining 
curcumin’s bioavailability.2-4 Curcumin is also found to 
be photo-sensitive and requires careful handling. In 
spite of numerous formulations challenges several 
formulation strategies like nanoparticles, liposomes,
complexation with phospholipids and cyclodextrins, 
solid dispersions are being developed to improve 
curcumin’s bioavailability.5-7 It is also popularly known 
as a hepatoprotective agent. 
      Liver is the main site of metabolism for many drugs 
and xenobiotics. The central role played by liver in the 
clearance and transformation of chemicals also makes it 
susceptible to drug induced injury. Liver fibrosis and 
liver cirrhosis are generally the end result of majority of 
chronic liver insults. The development of fibrosis, and 
particularly cirrhosis, are associated with a significant 
morbidity and mortality. The causes of hepatic fibrosis 
and cirrhosis are multiple and include congenital 
metabolic, inflammatory, and toxic liver diseases. In all 
circumstances, the composition of the hepatic scar is 
similar.8 Many chemicals damage mitochondria, an 
intracellular organelle that produces energy. Its 
dysfunction releases excessive amount of oxidants which 
in turn injures hepatic cells. Activation of some enzymes 
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in the cytochrome P-450 system such as CYP2E1 also 
leads to oxidative stress.9 This suggests that increase in 
oxidative stress is the center to the progression of these 
liver disorders. Further, injury to hepatocyte and bile 
duct cells lead to accumulation of bile acid inside liver. 
This promotes further liver damage and enhances 
inflammation.10 Non-parenchymal cells such as Kupffer 
cells, fat storing stellate cells, sinusoidal endothelial 
cells and leukocytes (i.e., neutrophils and monocytes) 
have a significant role in the mechanism.11 In all these 
conditions, curcumin which is both antioxidant as well 
as antiinflammatory should demonstrate significant 
benefit in liver toxicity. This was demonstrated by 
showing the hepatoprotective activity of curcumin. 
Interestingly, Kupffer cells in the liver are exposed to 
systemic circulation and are phagocytic in nature.12
Sinusoidal endothelial cells also exposed to systemic 
circulation can actively take up particles by
endocytosis.13 Thus, curcumin can be targeted to liver 
cells involved in fibrosis and cirrhosis using particulate 
approach in the way of passive targeting to improve the 
treatment of these liver disorders. Previous reports 
clearly indicate that smaller size particles are avidly 
taken up by liver cells compared to microparticles.13
Further, so as to target the liver, the size of the 
microparticles that can be injected into the systemic 
circulation is restricted to 6 µm only as the greater size 
particles are known to reach the lungs and gets lodged 
in the pulmonary tissues.14 Also, the amount of the drug 
released in the cells of interest with nanoparticles after 
cellular entrapment is far greater than compared to the 
release from the microparticles after cellular entrapment
because of the greater surface area of the 
nanoparticles.15 This could result in better 
pharmacodynamic activity with nanoparticles compared 
to the microparticles.  Thus, the objective of this study 
was to prepare the biodegradable nanoparticles 
containing curcumin, a well-known hepatoprotective 
agent and further to evaluate the liver targetability and 
sustained release of curcumin with the help of developed 
nanoformulation.
1. Materials and Methods
1.1. Materials
        Curcumin was procured from Yucca Enterprises, 
Mumbai. Poly-ε-caprolactone was procured from Sigma 
Aldrich, Germany. Poly vinyl alcohol was procured 
from Qualikems Fine Chemicals Pvt Ltd, New Delhi.
Chloroform was procured from Finar chemicals, 
Ahmedabad, India. HPLC solvents were procured from 
Merck specialities, Mumbai, India. SGOT and SGPT 
kits were purchased from Coral Clinical Systems, Goa, 
India.
1.2. Methods
1.2.1. Preparation of curcumin nanoparticles
    Double emulsion (W/O/W) solvent evaporation 
method was employed in the preparation of curcumin 
nanoparticles.16 Briefly, Curcumin and poly-ε-
caprolactone previously dissolved in 10 ml of 
chloroform was emulsified with 5 ml of 3% PVA 
solution under homogenization for 10min to form a 
W/O emulsion. This primary emulsion was thereafter 
poured into the 30 ml of PVA aqueous solution (3 % 
W/V) and homogenized in a homogenizer 
(Homogenizer 150 VT, M/S Biologics, Inc –USA) for 
15 min to form a W/O/W emulsions.17, 18 This multiple 
emulsion was stirred on a magnetic stirrer till complete 
evaporation of chloroform. The nanoparticles were 
obtained by centrifuging the resulted nanoparticular 
suspension at 10,000 rpm for 45 min. The obtained 
nanoparticles were washed with phosphate buffer saline
(PBS) and dried.
1.2.2. Characterization of the curcumin 
nanoparticles
Determination of the particle size and the surface
potential
      The prepared nanoparticles were evaluated for their 
particle size, polydispersity index(PDI) of size 
distribution and surface charge potential, by photon 
correlation spectroscopy (PCS) using Zetasizer 3000 
HAS (Malvern Instruments, Malvern, UK). The 
formulations were diluted 1:1000 with the aqueous 
phase of the formulation to get a suitable kilo counts per 
second (kcps). Analysis was performed at 25°C with an 
angle of detection of 90°.Each sample was measured in 
triplicate.
Encapsulation efficiency
      To determine the encapsulation efficiency, the drug 
from nanoparticles was extracted with acetonitrile, the 
obtained solution was evaporated to dryness and 
reconstituted with 100µl of mobile phase consisting of 
acetonitrile/methanol/water/acetic acid (40:23:36:1, 
v/v/v/v)(water and acetic acid solvents whose pH was 
adjusted to 2.8 prior to the preparation of mobile phase). 
The column used was C18 ODS column and the size of 
silica used in this column was 5μm and the dimension of 
the column was 4.6 × 250mm. The samples were spiked 
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into HPLC (Cyber Labs, USA) column and analysis was 
carried out a spectrophotometer at 230 nm. 19
In vitro release study
       In vitro release of Curcumin nanoparticles was 
performed by taking weighed amount of nanoparticles 
into a dialysis bag(D-70, MWCO 12000-2000, 
nanoparticles suspended in 1 ml of distilled water),
suspended in 50 ml of Phosphate Buffer 7.4 (release 
medium).20 This entire system was kept at 370C on 
magnetic stirrer with 50 rpm. Aliquots were withdrawn 
at predetermined time intervals and the receptor 
compartment was replenished with same volume of fresh 
dialysing medium. The samples were analyzed at 425 
nm using UV-Visible spectrophotometer (Elico SL 164 
Double beam). The release study was terminated when 
no more drug is released for more than 48 hours in the 
release conditions. Data obtained from in vitro release 
studies were fitted to various kinetic equations to find 
out the mechanism of curcumin release from the 
nanoparticles. 
Drug- polymer interactions
Drug – Polymer interaction was investigated using 
FTIR. FTIR spectra of drug, polymer, placebo 
nanoparticles and drug loaded particles were taken 
using a Thermo Nicolet Nexus 670 Spectrophotometer 
with KBr pellets.
ANIMAL STUDIES
IN VIVO DRUG RELEASE AND HEPATO
PROTECTIVE ACTIVITY OF THE 
FORMULATION
        In Vivo drug release was investigated in male wistar 
rats. All the animal experiments were conducted 
according to the rules and guidelines of Committee for 
the Purpose of Control and Supervision of Experiments 
on Animals (CPCSEA), Chennai, India. The study was 
approved by Institutional Animal Ethical Committee of 
Vaagdevi College of Pharmacy, Warangal, registered 
under CPCSEA, India (Registration No: 
1047/ac/07/CPCSEA). The rats were acclimatized
with 12 hour dark and 12 hour light cycle at a 
temperature of 20º C at a humidity of 60% and were 
fed on standard diet for 10 days prior to the 
commencement of the experiment. The conditions 
continued during the next 10 days of 
experimentation. Rats were divided into three groups,
each group containing six rats. Group 1 received 1ml of 
curcumin solution (15mg/ml DMSO solution)
intravenously. Group 2 received 1ml of curcumin 
nanoparticular suspension (equivalent to 15mg of 
curcumin) by intravenous route. Group 3 received 1ml
curcumin oral suspension (15mg). After administration 
of the formulations blood samples were collected at 0.5, 
1, 2, 3, 6, 12, 24 hours and 3, 6 and 9 days and plasma 
was separated. The drug was extracted from the plasma 
by adding 500 µl of acetonitrile. Curcumin in these
samples were estimated using a HPLC (Cyberlab, USA) 
at 230nm. In case of liver, kidney, colon and brain, the 
tissue was homogenized and then the drug was 
extracted with acetonitrile.  A HPLC standard curve for 
the drug in the plasma was generated. The mobile phase 
consisted of acetonitrile/methanol/water/acetic acid at 
a ratio of 40:23:36:1, v/v/v/v.
Hepatoprotective activity
     Carbon tetrachloride induced liver damage model 
was used in the evaluation of hepatoprotective activity 
of the prepared formulations. Male wistar rats (150-
180g) were divided into 5 groups containing six rats 
each. Group 1 received normal saline (1 ml/rat) daily for 
9 days. Group 2 received carbon tetrachloride (0.7 
ml/kg), administered intraperitoneally on the 3rd, 6th
and 9th day consisting of a mixture of CCl4 and olive oil 
(25:75). Group 3 received curcumin oral suspension (100 
mg/kg) daily for 9 days. Group 4 received curcumin 
solution (100mg/kg) intravenously, daily for 9 days. 
Group 5 received curcumin nanoparticular suspension 
(equivalent to 100mg/kg of curcumin) intravenously at 
day one. All groups received CCl4 at 3rd, 6th and 9th day 
of the study except normal control. Hepatoprotective 
activity was quantified by the SGOT (serum glutamate 
oxaloacetate transaminase), SGPT (serum glutamate 
pyruvate transaminase) levels and histological studies 
following a previously published report.21
Statistical analysis
       Results are expressed as means ± S.E.M. of six rats 
per treatment group. Data were analyzed using a one-
way analysis of variance (ANOVA) followed by 
Dunnett’s test. Differences were considered significant
at p≤0.05.
RESULTS
PREPARATION AND CHARACTERIZATION OF 
CURCUMIN NANOPARTICLES:
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      Curcumin nanoparticles were successfully prepared 
by double emulsion solvent evaporation method. Four 
formulations were prepared by taking different drug to 
polymer ratios like 1:1, 1:2, 1:3 and 1:4. Compositions of 
nanoparticles are described in Table 1. The results for 
particle size, zeta potential and encapsulation efficiency
are shown in Table 2. Drug polymer interactions were 
studied by FTIR; from the spectra we observed that 
there is no interaction between the drug and polymer.
The in vitro release studies from curcumin nanoparticles 
were fitted into various release kinetic models (Table 3). 
From release profiles (Fig. 1.) it was observed that 
increase in polymer concentration results in decrease of
drug release rate. From all four formulations, the drug 
release was up to 20% during the first 3 days. The 
percent cumulative drug release observed was 80%, 
86%, 90% and 92% and in vitro drug release was
sustained up to 6, 7, 9 and 12 days for CNP1, CNP2, 
CNP3 and CNP4, respectively. Different kinetic release 
patterns were evaluated. The log percent cumulative 
drug released was plotted as a function of log time and 
the slope of the curves was determined as the values of 
diffusional release exponent (n). The values of 
diffusional release exponent (n) from the straight lines 
were noted to be 0.395, 0.410, 0.421 and 0.422 for 
CNP1, CNP2, CNP3 and CNP4 respectively, which 
indicated that the release of drug from all formulations 
followed a Fickian pattern.22
IN VIVO DRUG RELEASE AND THE 
HEPATOPROTECTIVE ACTIVITY
      Drug levels in the plasma and the tissues were 
determined using HPLC. The retention time of the drug 
was 9.6 min. Plasma profile of the drug after 
nanoparticular, oral and i.v. solution form 
administration was plotted (Fig. 2.). From the figure it 
clearly indicates that nanoparticular formulation 
sustains the drug release up to 9 days reflecting in an 
increased area under curve. Peak serum concentration of 
2.2µg/ml was observed within 30 min when curcumin 
solution was given intravenously. Peak serum 
concentration of 1.12µg/ml was observed within 6 hours 
when curcumin suspension was given orally. Peak 
serum concentration of 2.6µg/ml was observed within 1 
hour when curcumin nanoparticles (CNP3) suspension
was given intravenously. Pharmacokinetic parameters 
were showed in Table 4. Data obtained from 
hepatoprotective study is shown in Table 5.
Nanoparticular formulation significantly reduces the 
elevated enzymes levels. From the table it was observed 
that all formulations were having significant
hepatoprotective activity when compared to CCl4
treated group (p <0.05).  Among all the formulations
studied, curcumin nanoparticles showed highest
hepatoprotective activity (Fig. 3.). The drug levels in 
various tissues like liver, brain, kidney, and colon were 
estimated and shown in Table 6. Histopathology of liver 
is shown in Fig. 4.
DISCUSSIONS
        Particle size and entrapment efficiency of the 
curcumin nanoparticles were increased with increasing 
the polymer content up to 300 mg. This is may be due 
to high amount of polymer available for coating the 
drug. Upon increasing the polymer amount, number of 
layers was increased; this resulted in the increase in 
particle size and entrapment efficiency. Further increase 
in the polymer content to 400 mg did not increase the
entrapment presumably due to the less availability of the 
drug to be incorporated. The in vitro drug release was 
fitted into various release models. From the release data 
we observed that increase in the polymer content delays 
the drug release due to increased particle size and 
reduced surface area available for drug release. From all 
the four formulations studied, formulation CNP3 was 
selected as optimized formulation because of less PDI, 
high entrapment efficiency and since the release was 
prolonged up to 9 days, the study period we selected for 
determining hepatoprotective activity.  From plasma 
profile it was observed that the drug levels in plasma 
was lower in case of curcumin when given orally
compared to that of curcumin and CNP3 given 
intravenously. This could be because of lower oral 
bioavailability of curcumin and significant degradation 
of free curcumin in the plasma. With the nanoparticular 
formulation the drug release was sustained up to 10 
days. This could be due to reduction in the elimination 
and metabolism. From the liver enzyme studies we 
observed that SGOT and SGPT levels were more in 
case of CCl4 treated animals because of tissue damage
caused by CCl4 which releases the enzymes in to the 
blood stream. A fatty layer was observed in the 
histopathology of liver. Upon administration of 
curcumin formulations the enzyme levels was decreased 
due to the fibrosis caused by the CCl4 was reversibly 
cured by the curcumin. The curability of liver toxicity 
was more for nanoparticles compared to the other 
formulations because of nanosize particles were 
instantly taken up by the RES of liver thus the drug was 
accumulated in the liver and the drug release was more 
concentrated at the cellular level of liver. This results in 
the hepatoprotection. After the treatment the fatty 
layers and number of necrotic cells were reduced due to 
the hepatoprotective action of curcumin. From tissue 
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distribution studies it was observed that drug was more 
concentrated in the liver compared to colon, kidney, and 
brain. This may be due to nanosize of the particles,
which were easily taken up by the RES of liver 
compared to the other tissues. The drug accumulation 
order in the different tissues is as follows: liver, colon, 
kidney and brain. The drug levels in brain were not 
detected and may due to the presence of blood brain 
barrier (BBB) which could hinder the transport of 
curcumin across the barrier. In case of nanoparticles 
small amount of drug was detected in the brain. This 
may be due to nanosize of the particles, which are 
accessible through the BBB. 
The results of this study clearly indicate that a 
nanoparticular formulation containing curcumin is 
better in pharmacokinetic properties and sustained 
plasma drug levels when compared to higher cumulative 
doses of curcumin administered via i.v. and oral 
administrations. The reversal of biochemical end points 
in a CCl4 hepatotoxic model is better with 
nanoparticular curcumin compared to oral and i.v. 
curcumin. This suggests that this formulation may be of 
potential use in the treatment of cirrhosis and fibrosis 
with curcumin. The results can be extrapolated to other 
drugs suggesting the significant benefits of 
nanoparticular passive targeting of drugs to the liver. 
Similar formulations could not only be used in fibrosis 
and cirrhosis but also could be used in the liver cancers 
and several other liver diseases with additional benefits
    Table 1. Compositions of curcumin nanoparticles.
Formulation code CNP1 CNP2 CNP3 CNP4
Curcumin (mg) 100 100 100 100
Poly-ε-caprolactone (mg) 100 200 300 400
      Table 2. The particle size, zeta potential and encapsulation efficiencies of curcumin nanoparticles.
Formulation code
Particle size
(mean±SD) nm*
Polydispersity 
Index (PDI)
Zeta potential 
(mean±SD)*
% Encapsulation Efficiency 
(mean±SD)*
CNP1 300 ± 1.63 0.525 2.85±2.33 74.75 ± 3.45
CNP2 20.45 ± 1.63 0.325 2.56±3.54 78.41 ± 2.15
CNP3 364.82 ± 3.25 0.103 2.91±2.83 83.25 ± 1.24
CNP4 464.12± 5.48 0.356 2.81±2.55 85.03 ± 0.75
* n=3
Table 3. The in vitro release studies from curcumin nanoparticles were fitted into various release kinetic models.
Formulation code
Zero order First order Higuchi model Korsemeyer - Peppas model
R2 R2 R2 R2 N
CNP1 0.9271 0.9850 0.9905 0.9910 0.395
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CNP2 0.9533 0.9872 0.9947 0.9922 0.410
CNP3 0.9511 0.9909 0.9956 0.9928 0.421
CNP4 0.9223 0.9978 0.9923 0.9918 0.422
          Table 4. Pharmacokinetic parameters obtained after administration of curcumin formulations.
Parameter
Curcumin oral suspension  
15mg)
Curcumin iv bolus 
(15 mg)
Curcumin 
nanoparticles iv
Cmax(µg/ml) 1.12±0.056 2.2±0.024 2.6±0.15
Ke(per hour) 0.106±0.008 0.14±0.004 0.004±0.0008
T1/2(hours) 6.53±0.45 4.69±0.3 165.4134±1.57
Vd(Litres) 8.39±0.95 7.99±0.54 9.23±0.45
Clearance( L/h) 0.8±0.034 1.1798±0.06 0.0386±0.004
AUC0∞(µg/ml/h) 16.835±2.548 12.713±2.658 387.649±10.54
              * Values indicate mean ± standard error mean (S.E.M). n=6
Table 5. Effect of curcumin formulations on enzyme levels in rats with CCl4 induced hepatotoxicity (Mean ± SEM; n=3)
Groups SGOT( U/L) SGPT( U/L)
Normal control( saline ) 16.09±1.306 10.73±2.359
CCl4 treatment 73.39±2.45b 43.79±3.485b
CCl4 + Curcumin oral(100mg/kg) 41.44±3.611a 26.16±2.955 a
CCl4 + Curcumin i.v (10mg/kg) 33.07±2.571 a 20.82±2.767 a
CCl4 + Curcumin nanoparticles (100mg/kg) 21.02±1.01 a 14.81±2.881 a.
Note: a p < 0.05 vs CCl4 treated, b p < 0.05 vs normal control
Table 6. Curcumin levels in various tissues (µg/mg).
Tissue Curcumin oral suspension Curcumin i.v solution Curcumin nanoparticles
Liver 15.26 ± 0.958 24.78 ± 2.35 56.254 ± 3.54
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Colon 8.01 ± 1.2 9.24 ± 1.25 15.614 ± 1.65
Kidney 0.954 ± 0.125 1.256 ± 0.547 2.658 ± 0.954
Brain Not detectable Not detectable 0.076 ± 0.015
                            * All values in µg/mg of tissue. n=6
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CONCLUSION 
The nanoparticular formulations of curcumin were 
successfully prepared using double emulsion (W/O/W) 
solvent evaporation method. The drug release from the 
formulations was sustained up to 10 days. The in vivo 
performance of the formulation was better compared to 
the respective oral and i.v formulations. From the 
distribution studies it was concluded that better liver 
targeting was achieved by the nanoformulations 
compared to oral and i.v. formulations.
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